Biodexa Pharmaceuticals (BDRX) Competitors $4.40 +0.12 (+2.80%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends BDRX vs. RNAZ, BON, GLMD, PBLA, SXTC, VRPX, ERNA, PBM, ONCT, and ATNFShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include TransCode Therapeutics (RNAZ), Bon Natural Life (BON), Galmed Pharmaceuticals (GLMD), Panbela Therapeutics (PBLA), China SXT Pharmaceuticals (SXTC), Virpax Pharmaceuticals (VRPX), Eterna Therapeutics (ERNA), Psyence Biomedical (PBM), Oncternal Therapeutics (ONCT), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. TransCode Therapeutics Bon Natural Life Galmed Pharmaceuticals Panbela Therapeutics China SXT Pharmaceuticals Virpax Pharmaceuticals Eterna Therapeutics Psyence Biomedical Oncternal Therapeutics 180 Life Sciences Biodexa Pharmaceuticals (NASDAQ:BDRX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends. Does the media refer more to BDRX or RNAZ? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 1 mentions for Biodexa Pharmaceuticals and 0 mentions for TransCode Therapeutics. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score. Company Overall Sentiment Biodexa Pharmaceuticals Neutral TransCode Therapeutics Neutral Is BDRX or RNAZ more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A TransCode Therapeutics N/A -649.03%-281.34% Do analysts rate BDRX or RNAZ? Biodexa Pharmaceuticals currently has a consensus target price of $200.00, indicating a potential upside of 4,445.45%. TransCode Therapeutics has a consensus target price of $20.00, indicating a potential upside of 468.18%. Given Biodexa Pharmaceuticals' higher possible upside, equities analysts plainly believe Biodexa Pharmaceuticals is more favorable than TransCode Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor BDRX or RNAZ? TransCode Therapeutics received 12 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 92.86% of users gave TransCode Therapeutics an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesTransCode TherapeuticsOutperform Votes1392.86% Underperform Votes17.14% Which has stronger earnings & valuation, BDRX or RNAZ? Biodexa Pharmaceuticals has higher revenue and earnings than TransCode Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K1.12-$7.66MN/AN/ATransCode TherapeuticsN/AN/A-$18.55MN/AN/A Which has more volatility & risk, BDRX or RNAZ? Biodexa Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Do institutionals & insiders hold more shares of BDRX or RNAZ? 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryBiodexa Pharmaceuticals beats TransCode Therapeutics on 9 of the 11 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$528,000.00$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / Sales1.12335.611,282.2680.28Price / CashN/A22.6336.6032.90Price / Book0.105.084.964.69Net Income-$7.66M$154.90M$117.89M$224.57M7 Day Performance5.26%2.59%2.75%3.33%1 Month Performance10.28%1.52%3.63%5.33%1 Year PerformanceN/A5.49%27.27%22.97% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals1.8725 of 5 stars$4.40+2.8%$200.00+4,445.5%N/A$528,000.00$470,000.000.0020RNAZTransCode Therapeutics1.8165 of 5 stars$2.82-14.0%$20.00+609.2%-99.6%$1.96MN/A0.009Positive NewsHigh Trading VolumeBONBon Natural LifeN/A$1.64-1.8%N/A-71.6%$1.93M$25.56M0.00100Positive NewsGLMDGalmed Pharmaceuticals1.87 of 5 stars$2.92+0.7%N/A-28.3%$1.88MN/A-0.1820Positive NewsPBLAPanbela TherapeuticsN/A$0.37+0.6%N/A-94.6%$1.81MN/A-0.016Gap DownSXTCChina SXT Pharmaceuticals0.1361 of 5 stars$0.43-8.1%N/A-75.9%$1.75M$1.93M0.0090Positive NewsGap DownVRPXVirpax Pharmaceuticals1.3714 of 5 stars$0.36-2.7%$3.00+745.1%-90.2%$1.74MN/A0.007News CoveragePositive NewsERNAEterna Therapeutics1.0854 of 5 stars$0.30+0.7%N/A-69.8%$1.64M$598,000.00-0.0410Gap UpPBMPsyence BiomedicalN/A$1.93+13.6%N/AN/A$1.63MN/A0.00N/APositive NewsGap DownHigh Trading VolumeONCTOncternal Therapeutics1.4582 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530ATNF180 Life SciencesN/A$1.45-4.0%N/A-59.9%$1.48MN/A0.007Analyst ForecastNews CoveragePositive NewsGap Up Related Companies and Tools Related Companies TransCode Therapeutics Competitors Bon Natural Life Competitors Galmed Pharmaceuticals Competitors Panbela Therapeutics Competitors China SXT Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Eterna Therapeutics Competitors Psyence Biomedical Competitors Oncternal Therapeutics Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDRX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDRX Stock Alerts